Half-yearly Report

Bioventix plc                                 

           INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2012           

Bioventix plc (BVXP) ("Bioventix" or "the Company"), a UK company specialising
in the development and commercial supply of high-affinity monoclonal antibodies
for applications in clinical diagnostics, announces its unaudited interim
financial results for the six-month period ending 31 December 2012.

                                  HIGHLIGHTS                                   

  * Turnover: £1.18m (2011: £1.30m)
   
  * Profit after tax: £630,160 (2011: £700,085)
   
  * 2012 year end cash: £2.31m (2011: £1.94m)
   
  * Interim dividend per share: 5.8p (March 2012: 4.84p)
   
                   CHAIRMAN AND CHIEF EXECUTIVE'S STATEMENT                    

We are pleased to report the results for the half-year ended 31 December 2012.
Revenues for the half-year period of £1.18m (2011:£1.30m) were down on the
equivalent period last year. Whilst royalty revenue remained robust throughout
the period, lower sales of physical antibodies accounted for the reduced
revenue compared to 2011. The sales of these products are inherently irregular
in nature as many customers order only once every year or two as a consequence
of production scheduling.

Profit after tax was also lower at £630,160 (2011:£700,085) but we were able to
take advantage of increased R&D tax credits that have been announced in recent
budgets. Cash balances at 31 December 2012 of £2.31m (2011: £1.94m) were
significantly higher than the previous year.

We have reported previously on our positive outlook for our vitamin D
activities and a leading antibody called vitD3.5H10. Revenue from this product
has been significant and royalties are now being generated as customer products
(assays for vitamin D deficiency) reach markets around the world. Progress in
the US has been slower as would be expected due to the FDA regulatory approval
process.

The Company remains committed to developing new antibodies for
commercialisation and has continued its R&D activities to enhance the future
pipeline. The continued achievements of the Company would not be possible
without the on-going contribution from the scientists and support staff at the
Company and we would like to thank them for their efforts which underpin our
success.

The Board remains confident that the Company will continue the progress it has
made over the last few years and is pleased to declare an increased interim
dividend of 5.8p per Ordinary share (2012: 4.84p) continuing the progressive
dividend policy adopted since 2010. The shares will be marked ex-dividend on 10
April 2013 and the dividend will be paid on 17 April 2013 to shareholders on
the register at close of business on 12 April 2013.

During October 2013, ICAP re-launched the market on which Bioventix shares are
traded as the ISDX Growth Market. We are encouraged by the re-launch of the
market and remain optimistic about its future prospects as part of the ICAP
group.

Significantly, during December 2012, funds under the Miton portfolio acquired
22.7% of Bioventix plc. Previously known as MAM Funds, Miton is managed by
Gervais Williams and Martin Turner and is highly regarded in the small-cap
funds sector and we are delighted to welcome them to the Bioventix shareholder
register.

P J Harrison
Chief Executive Officer

I J Nicholson
Non-Executive Chairman

                                 BIOVENTIX PLC                                 

                            PROFIT AND LOSS ACCOUNT                            

                for the six month period ended 31 December 2012                

                                                      Six months     Six months
                                                           ended          ended
                                                     31 Dec 2012    31 Dec 2011
                                                                               
                                                               £              £
                                                                               
TURNOVER                                               1,181,353      1,298,428
                                                                               
Cost of sales                                           (88,357)       (73,475)
                                                                               
GROSS PROFIT                                           1,092,996      1,224,953
                                                                               
Administrative expenses                                (363,140)      (356,451)
                                                                               
OPERATING PROFIT                                         729,856        868,502
                                                                               
Interest receivable                                        6,887          5,230
                                                                               
Interest payable                                            (97)              -
                                                                               
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION            736,646        873,732
                                                                               
Tax on profit on ordinary activities                   (106,486)      (173,647)
                                                                               
PROFIT FOR THE FINANCIAL PERIOD                          630,160        700,085
                                                                               

                                                                               
                                 BIOVENTIX PLC                                 

                                 BALANCE SHEET                                 

                            as at 31 December 2012                             

                                               31 Dec 2012       31 Dec 2011
                                                                            
                                                         £                 £
                                                                            
FIXED ASSETS                                                                
                                                                            
Intangible fixed assets                             20,000            40,000
                                                                            
Tangible fixed assets                              442,618           448,419
                                                                            
                                                   462,618           488,419
                                                                            
CURRENT ASSETS                                                              
                                                                            
Stocks                                             111,797           111,507
                                                                            
Debtors                                            913,893           755,984
                                                                            
Cash at bank and in hand                         2,312,261         1,940,437
                                                                            
                                                 3,337,951         2,807,928
                                                                            
CREDITORS:amounts falling due within one         (187,918)         (243,017)
year                                                                        
                                                                            
NET CURRENT ASSETS                               3,153,033         2,564,911
                                                                            
TOTAL ASSETS LESS CURRENT LIABILITIES            3,612,651         3,053,330
                                                                            
PROVISIONS FOR LIABILITIES                                                  
                                                                            
Deferred Tax                                       (7,651)           (7,527)
                                                                            
NET ASSETS                                       3,605,000         3,045,803
                                                                            
CAPITAL AND RESERVES                                                        
                                                                            
Called up share capital                            251,269           251,269
                                                                            
Capital redemption reserve                           1,231             1,231
                                                                            
Profit and loss account                          3,352,500         2,793,303
                                                                            
SHAREHOLDERS' FUNDS                              3,605,000         3,045,803

BIOVENTIX PLC

Notes to the financial information

 1. While the interim financial information has been prepared using the
    company's accounting policies and in accordance with UK GAAP, the
    announcement does not itself contain sufficient information to comply with
    UK GAAP.
   
 2. This interim financial statement has not been audited or reviewed by the
    auditors.
   
The Directors of Bioventix plc accept responsibility for this announcement.

For further information, please contact:

Bioventix plc
Peter Harrison
Tel: [phone]

Keith, Bayley, Rogers & Co. Limited
David Coffman
Tel: [phone]